F Park1,2, K Russo1, P Williams1,3, M Pelosi2, R Puddephatt2, M Walter2, C Leung1, R Saaid2,4, H Rawashdeh2, R Ogle2, J Hyett1,2. 1. Central Clinical School, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia. 2. RPA Women and Babies, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 3. Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 4. Department of Obstetrics and Gynaecology, University of Malaya, Kuala Lumpur, Malaysia.
Abstract
OBJECTIVE: To examine the effect of a combination of screening and treatment with low-dose aspirin on the prevalence of early-onset pre-eclampsia (PE). METHODS: This was a retrospective analysis of two consecutive cohorts of women screened for early PE. The first cohort was observed to determine whether algorithms developed to screen for PE at 11 to 13 + 6 weeks' gestation could be applied to our population. High-risk women in the second cohort were advised on their risk and offered aspirin (150 mg at night), with treatment starting immediately after screening. The prevalence of early PE and the proportion of women with PE delivering at 34-37 weeks' gestation were compared between the cohorts. RESULTS: In the observational and interventional cohorts, 3066 and 2717 women, respectively, were screened. There were 12 (0.4%) cases of early PE in the observational cohort and one (0.04%) in the interventional cohort (P < 0.01). Among all women with PE delivering before 37 weeks, 25 (0.83%) were in the observational cohort and 10 (0.37%) in the interventional cohort (P = 0.03). CONCLUSIONS: A strategy of first-trimester screening for early PE coupled with prescription of aspirin to the high-risk group appears to be effective in reducing the prevalence of early PE.
OBJECTIVE: To examine the effect of a combination of screening and treatment with low-dose aspirin on the prevalence of early-onset pre-eclampsia (PE). METHODS: This was a retrospective analysis of two consecutive cohorts of women screened for early PE. The first cohort was observed to determine whether algorithms developed to screen for PE at 11 to 13 + 6 weeks' gestation could be applied to our population. High-risk women in the second cohort were advised on their risk and offered aspirin (150 mg at night), with treatment starting immediately after screening. The prevalence of early PE and the proportion of women with PE delivering at 34-37 weeks' gestation were compared between the cohorts. RESULTS: In the observational and interventional cohorts, 3066 and 2717 women, respectively, were screened. There were 12 (0.4%) cases of early PE in the observational cohort and one (0.04%) in the interventional cohort (P < 0.01). Among all women with PE delivering before 37 weeks, 25 (0.83%) were in the observational cohort and 10 (0.37%) in the interventional cohort (P = 0.03). CONCLUSIONS: A strategy of first-trimester screening for early PE coupled with prescription of aspirin to the high-risk group appears to be effective in reducing the prevalence of early PE.
Authors: Jonathan B Carmichael; Hsiao-Pin Liu; David Janik; Terrence W Hallahan; Kypros H Nicolaides; David A Krantz Journal: Prenat Diagn Date: 2017-07-18 Impact factor: 3.050